Food and Staples Retailing Drug Retail

More

  • Spark Therapeutics' eying FDA approval Monday, 5 Oct 2015 | 8:00 AM ET
    Spark Therapeutics' eying FDA approval

    Spark Therapeutics' gene therapy for rare, inherited forms of blindness met the goals of a late-stage study.

  • Promising results on arthritis drug Friday, 25 Sep 2015 | 8:00 AM ET
    Promising results on arthritis drug

    AbbVie said its experimental drug improved symptoms of rheumatoid arthritis in patients in two mid-stage studies.

  • Biotech CEO speaks out after Turing price hike Wednesday, 23 Sep 2015 | 8:20 AM ET
    Biotech CEO speaks out after Turing price hike

    CNBC's Meg Tirrell speaks to Alnylam Pharmaceuticals CEO John Maraganore, about drug pricing in the U.S.

  • Hillary Clinton outlines drug cost plan Tuesday, 22 Sep 2015 | 3:55 PM ET
    Hillary Clinton outlines prescription cost plan

    Democratic presidential candidate Hillary Clinton unveils her plan to lower prescription drug costs.

  • Hillary Clinton: I want to put an end to profiteering

    Democratic presidential candidate Hillary Clinton addresses innovation in the pharmaceutical and biotech industries, and unveils her plan to lower prescription drug costs.

  • Your money or your life? Tuesday, 22 Sep 2015 | 1:46 PM ET
    Your money or your life?

    Dr. Peter Bach, MD of Memorial Sloan Kettering Cancer Center, weighs in on Turing Pharmaceuticals' decision to increase a single dose of Daraprim from $13.50 to $750.

  • Clinton lays out drug plan Tuesday, 22 Sep 2015 | 10:20 AM ET
    Democratic Presidential candidate Hillary Clinton speaks during a community forum on substance abuse September 17, 2015 in Laconia, New Hampshire.

    CNBC's Meg Tirrell reports on Hillary Clinton's drug plan, one day after she criticized drug price gouging.

  • High costs for drug development Monday, 21 Sep 2015 | 1:38 PM ET
    High costs for drug development

    Hillary Clinton is criticizing drug price gouging. Steve Case, Revolution Chairman and CEO, shares his take.

  • Drug price outrage Monday, 21 Sep 2015 | 12:34 PM ET
    Drug price outrage

    Hillary Clinton is criticizing drug price gouging, after news a drug company hiked the price of one of its drugs by 5,000 percent overnight, with CNBC's Meg Tirrell.

  • *Forecasts profit of $0.12- $0.19/ shr. Sept 17- Drugstore chain operator Rite Aid Corp cut its full-year forecasts for total earnings and drugstore sales, citing lower pharmacy reimbursements and expenses related to its $2 billion acquisition of pharmacy benefit manager EnvisionRx. Rite Aid shares fell nearly 9 percent in morning trading on Thursday.

  • Sept 17- Drugstore chain operator Rite Aid Corp cut its full-year forecast for drugstore sales and total earnings, citing "recent sales trends" and expenses related to its $2 billion acquisition of pharmacy benefit manager EnvisionRx. Rite Aid cut its drugstore sales forecast for the year ending February to $26.7 billion- $27.0 billion from $26.9 billion-...

  • Sept 17- Drugstore chain operator Rite Aid Corp reported a 17.5 percent rise in quarterly revenue, helped by its $2 billion acquisition of pharmacy benefit manager EnvisionRx. Net income fell to $21.5 million, or 2 cents per share, in the second quarter ended Aug. 29, from $127.8 million, or 13 cents per share, a year earlier. Revenue rose to $7.66 billion from $6.52...

  • Heart of California's marijuana industry Wednesday, 16 Sep 2015 | 11:05 AM ET
    Heart of California's marijuana industry

    CNBC's Jane Wells reports from Arcata, California, where the city council wants to build the country's first marijuana innovation zone.

  • Lifesaving blood pressure study Friday, 11 Sep 2015 | 1:09 PM ET
    Lifesaving blood pressure study

    A new government study on blood pressure found potentially lifesaving results, reports CNBC's Meg Tirrell.

  • A setback for GSK Wednesday, 9 Sep 2015 | 10:00 AM ET
    A setback for GSK

    Disappointing clinical results for GSK-Theravance respiratory treatment.

  • CHICAGO, Sept 3- CVS Health Corp said on Thursday its decision to stop selling tobacco products last year led to a 1 percent decrease in cigarette sales in some states where the drugstore chain has a sizeable presence. The September 2014 decision hurt sales, with general merchandise revenue at CVS pharmacies open at least a year falling 7.8 percent in the second...

  • Amgen approved for pricey new drug Friday, 28 Aug 2015 | 6:00 AM ET
    Amgen approved for pricey new drug

    Amgen wins FDA approval for cholesterol-lowering drug Repatha.

  • Abbott denies rumors on St. Jude deal Thursday, 27 Aug 2015 | 8:00 AM ET
    Abbott denies rumors on St. Jude deal

    Abbott denies FT speculation about a St. Jude's acquisition.

  • Valeant bets on pink pill Thursday, 20 Aug 2015 | 3:24 PM ET
    Valeant bets on pink pill

    Shares of Valeant are down 6 percent after buying Sprout Pharmaceuticals, the maker of the "female Viagra" drug. CNBC's Meg Tirrell discusses drug deals.

  • 'Female Viagra' sparks interest in Valeant Thursday, 20 Aug 2015 | 8:00 AM ET
    'Female Viagra' sparks interest in Valeant

    Valeant to purchase flibanserin-maker Sprout for $1 billion.